Courses

This CME program is derived from content presented at the 2020-2021 Eastern Pulmonary Conference Program. The expert faculty, Drs. Sidney S. Braman and M. Patricia Rivera, will first provide a review of current science in non-small cell lung cancer (NSCLC), including trends in stage distribution of lung cancer. Following, current data for targeted therapies as well as immunotherapies in various ...
View Course

This continuing medical education series includes three, 30-minute serialized, educational interviews, designed to bring clinicians up to date on novel therapeutic advances to improve outcomes in patients with tenosynovial giant cell tumor (TGCT). Tenosynovial giant cell tumor is a rare tumor that often leads to severe morbidity or functional limitations. TGCT is categorized into two subtypes, localized and diffuse, where ...
View Course

In this module, Ryan B. Corcoran, MD PhD, along with Scott Kopetz, MD, PhD, course chair, will highlight current clinical trial data for BRAF and Anti-PD-1 targeted therapeutic options in the colorectal cancer treatment landscape. The expert faculty will provide an in-depth review of novel studies by analyzing study populations, methods and results, as well as providing key takeaways for ...
View Course

In this module, Michael J. Overman, MD, along with Scott Kopetz, MD, PhD, course chair, will review clinical trial data of approved and emerging targeted Anti-PD-1-based therapies for the treatment of patients with colorectal cancer, debating the clinical relevance of each in a discussion-based format. The toxicity spectrum of immune-related adverse events will be covered, along with kinetics. Current treatment ...
View Course

In this module, Jonathan Loree, MD, MS, along with Scott Kopetz, MD, PhD, course chair, will first provide a brief overview of the history and prevalence of colorectal cancer, as well as best practices for screening. Following, the expert faculty will review the role of clinically relevant biomarkers in metastatic colorectal cancer. Strategies for detecting and managing various prevalent mutations ...
View Course

In this module, Jamie Faber, PA-C and Tracy Trevino, BSN, RN, along with Scott Kopetz, MD, PhD, course chair, will highlight the role of the interprofessional team in administering optimal patient education and promoting compliance. Practical recommendations for addressing disparities in patient care will also be provided. Further, the expert faculty will discuss side effect management and best practices for ...
View Course

This CE activity is designed to educate healthcare providers involved in the prevention and management of prostate cancer by presenting the most recent information applicable to clinical practice, with the ultimate goal of improving patient care. Dr. Matthew Smith focuses on recent clinical trials in castration-resistant prostate cancer and the efficacy and safety data outcomes as well as the role ...
View Course

In this module, Jonathan Loree, MD, MS, along with Scott Kopetz, MD, PhD, course chair, will first provide a brief overview of the history and prevalence of colorectal cancer, as well as best practices for screening. Following, the expert faculty will review the role of clinically relevant biomarkers in metastatic colorectal cancer. Strategies for detecting and managing various prevalent mutations ...
View Course

In this module, Van Karlyle Morris, MD, along with Scott Kopetz, MD, PhD, course chair, will highlight current strategies for targeting MAPK signaling in colorectal cancer (CRC). Recent clinical trial data for BRAF-mutated CRC, particularly various survival outcomes data, will be reviewed and clinical relevance debated throughout the interview. The emerging role of immunotherapy will also be evaluated. Upon completion ...
View Course

In this module, Rona Yaeger, MD, along with Scott Kopetz, MD, PhD, course chair, will first cover strategies for modulating toxicity of targeted therapies for BRAF V600E colorectal cancer (CRC). The expert faculty will discuss best practices for improving the therapeutic index to target non-V600 BRAF mutant CRC through a discussion-based format. Recent clinical trial data, including that of the ...
View Course